{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:07:38Z","timestamp":1785240458598,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:54:25Z","timestamp":1777046065000},"page":"e978-e985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and NextQuestions | Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Tamer","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2026.04.011_bib0001","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41375-018-0039-7","article-title":"Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group (COG)","volume":"32","author":"Gupta","year":"2018","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2026.04.011_bib0002","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.04.011_bib0003","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.04.011_bib0004","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2026.04.011_bib0005","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3889\/oamjms.2019.752","article-title":"Clinical significance of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia","volume":"7","author":"Jovanovska","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"issue":"7","key":"10.1016\/j.clml.2026.04.011_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.04.011_bib0007","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.04.011_bib0008","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2026.04.011_bib0009","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"issue":"10299","key":"10.1016\/j.clml.2026.04.011_bib0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.clml.2026.04.011_bib0011","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-017-0565-x","article-title":"Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat it","volume":"19","author":"Short","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0013","first-page":"241","article-title":"Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome","volume":"105","author":"Griesinger","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.04.011_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101407","article-title":"Measurable residual disease in acute lymphoblastic leukemia: how low is low enough?","volume":"35","author":"Logan","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.04.011_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104506","article-title":"Validation study of analytical methods for multiparameter flow cytometry-based measurable residual disease assessment in acute myeloid leukemia","volume":"26","author":"Barone","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2026.04.011_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70202","article-title":"Validation of an adapted NGS-based clonality assay for MRD monitoring in B-ALL using archived and follow-up samples","volume":"6","author":"Suryavanshi","year":"2025","journal-title":"EJHaem"},{"issue":"13","key":"10.1016\/j.clml.2026.04.011_bib0019","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2026.04.011_bib0020","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2011.060426","article-title":"Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"97","author":"Gaipa","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0021","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2026.04.011_bib0022","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"52","key":"10.1016\/j.clml.2026.04.011_bib0023","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1073\/pnas.1118357109","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan","year":"2011","journal-title":"Proc Nat Acad Sci"},{"issue":"26","key":"10.1016\/j.clml.2026.04.011_bib0024","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.04.011_bib0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2026.04.011_bib0026","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Br\u00fcggemann","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.011_bib0027","unstructured":"Available at: https:\/\/adaptivebiotech.showpad.com\/share\/Tyh1kHj3ORA5oD14VlSd8. Accessed: March 14, 2026."},{"issue":"8","key":"10.1016\/j.clml.2026.04.011_bib0028","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+\u2009ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2026.04.011_bib0029","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"10.1016\/j.clml.2026.04.011_bib0031","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2026.04.011_bib0032","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1080\/10428194.2020.1811272","article-title":"Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"61","author":"Arunachalam","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.clml.2026.04.011_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2020.06.003","article-title":"Monitoring MRD in ALL: methodologies, technical aspects and optimal time points for measurement","volume":"57","author":"Bartram","year":"2020","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0034","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2026.04.011_bib0035","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.011_bib0036","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288671","article-title":"Two episodes of ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up","author":"Rubio-San-Sim\u00f3n","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.04.011_bib0037","first-page":"795","article-title":"Lineage involvement by BCR\/ABL in ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs ph+ acute lymphoblastic leukemia","volume":"10","author":"Anastasi","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.011_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586567","article-title":"Multi-lineage BCR-ABL expression in Philadelphia chromosome-positive acute lymphoblastic leukemia is associated with improved prognosis but no specific molecular features","volume":"10","author":"Nishiwaki","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.011_bib0039","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2025-551","volume":"146","author":"Maroun","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.011_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586567","article-title":"Multi-lineage BCR-ABL expression in Philadelphia chromosome-positive acute lymphoblastic leukemia is associated with improved prognosis but no specific molecular features","volume":"10","author":"Nishiwaki","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1525-1578(10)60530-2","article-title":"Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR","volume":"6","author":"Chasseriau","year":"2004","journal-title":"J Mol Diagn"},{"issue":"12","key":"10.1016\/j.clml.2026.04.011_bib0042","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3324\/haematol.11737","article-title":"Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia","volume":"92","author":"Thomas","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.011_bib0043","article-title":"P100: BCR\/ABL1 p230 transcript in B-lymphoblastic leukemia\/lymphoma: a case report","volume":"2","author":"Taghiyev","year":"2024","journal-title":"Genet Med Open"},{"issue":"3","key":"10.1016\/j.clml.2026.04.011_bib0044","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2026.04.011_bib0046","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","article-title":"Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value","volume":"101","author":"Vidriales","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.04.011_bib0047","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajh.25671","article-title":"The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival","volume":"95","author":"Yilmaz","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0048","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.011_bib0049","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia group ALL 4-2002 MRD study","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.011_bib0050","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2023.11.002","article-title":"Concordance of next-generation sequencing and multiparametric flow cytometry methods for detecting measurable residual disease in adult acute lymphoblastic leukemia: optimizing prediction of clinical outcomes from a single-center study","volume":"24","author":"Ashouri","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.clml.2026.04.011_bib0051","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0052","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0053","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-025-01373-y","article-title":"Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL","volume":"15","author":"Short","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2026.04.011_bib0054","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2017.76.0504","article-title":"Integrated risk stratification using minimal residual disease and sentinel genetic alterations in pediatric acute lymphoblastic leukemia","volume":"36","author":"Hunger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0056","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O\u2019Connor","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.011_bib0057","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.04.011_bib0058","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2026.04.011_bib0059","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph\u2013B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0061","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.04.011_bib0062","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.011_bib0063","article-title":"Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia","author":"Nguyen","year":"2020","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.011_bib0064","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1182\/blood-2024-201610","article-title":"NGS MRD negativity on day 28 after Brexu Cel in adults with R\/R ALL is associated with favorable progression free survival","volume":"144","author":"Valtis","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.04.011_bib0065","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0066","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.clml.2026.04.011_bib0067","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2026.04.011_bib0068","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2026.04.011_bib0069","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171751","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.04.011_bib0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2026.04.011_bib0071","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.011_bib0072","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.04.011_bib0073","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.04.011_bib0074","first-page":"12","article-title":"Can CAR T-cell therapy be a definitive treatment for adult r\/r B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucel","volume":"25","author":"Park","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2026.04.011_bib0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood.2025029611","article-title":"Age-adapted chemotherapy and MRD-oriented transplant for ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial","volume":"147","author":"Boissel","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.011_bib0076","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk Res Treatment"},{"issue":"9","key":"10.1016\/j.clml.2026.04.011_bib0077","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41409-025-02632-z","article-title":"Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study","volume":"60","author":"Cavallaro","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2026.04.011_bib0078","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2026.04.011_bib0079","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2019004685","article-title":"Impact of TKIs post\u2013allogeneic hematopoietic cell transplantation in Philadelphia chromosome\u2013positive ALL","volume":"136","author":"Saini","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2026.04.011_bib0080","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:56:08Z","timestamp":1785239768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001114"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and NextQuestions | Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}